slide 1:

Stargardt Disease Market Insight Epidemiology and Market Forecast 2030 Stargardt Disease market key facts ● The estimated prevalence of Stargardt Disease is around 1 in 8000 to 10000 individuals. ● In the UK the annual incidence for Stargardt Disease was between 0.110 and 0.128 per 100 000 individuals. ● Stargardt Disease is the most commonly inherited childhood and adulthood maculopathy ● Around 30000 people in the U.S are affected by Stargardt Disease. Stargardt Disease market report Key benefits ● DelveInsights " Stargardt Disease Market Insights Epidemiology and Market Forecast 2030 report delivers an in-depth understanding of the Stargardt Disease historical and forecasted epidemiology as well as the Stargardt Disease STGD market trends in the seven major markets i.e United States EU5 Germany Spain Italy France and United Kingdom and Japan. ● The STGD market report provides Stargardt Disease current treatment practices emerging drugs and market share of the individual therapies current and forecasted Stargardt Disease STGD market Size from 2017 to 2030 segmented by seven major markets. ● The Report also covers current Stargardt Disease STGD market drivers market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. ● The report provides insights into different therapeutic candidates in Stargardt Disease Phase II and Phase III stage. ● It also analyses Stargardt Disease STGD key players involved in developing targeted therapeutics. Some of the key players in the Stargardt Disease market include Astellas Pharma Acucela Pharmaceuticals Alkeus Pharmaceuticals and many others. ● The launch of the emerging therapies is expected to significantly impact Stargardt Disease treatment scenario in the upcoming years. Some of the drugs covered in the report include ALK-001 Emixustat ASP7317 And many others About DelveInsight DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.